<p>New Delhi: Glenmark Pharmaceuticals is recalling close to 15 lakh bottles of a generic medication used in the treatment of attention deficit hyperactivity disorder in the US market, according to the US health regulator.</p>.<p>Glenmark Pharmaceuticals Inc, USA, a subsidiary of the Mumbai-based drug maker, is recalling around 14.76 lakh bottles of Atomoxetine Capsules in multiple strengths.</p>.<p>The company is recalling the affected lot due to "CGMP Deviations", the US Food and Drug Administration (USFDA) said in its latest Enforcement Report.</p>.Glenmark, Cosmo get MHRA nod for acne treatment medication.<p>The recall is due to "presence of N-Nitroso Atomoxetine impurity above the FDA recommended limit," it added.</p>.<p>New Jersey-based Glenmark Pharmaceuticals Inc, USA is recalling the made-in-India product in strengths ranging from 10 mg to 100 mg, USFDA stated.</p>.<p>The company initiated the Class II recall on January 29 this year.</p>.<p>As per the USFDA, a Class II recall is initiated in a situation in which use of, or exposure to, a violative product may cause temporary or medically reversible adverse health consequences or where the probability of serious adverse health consequences is remote.</p>.<p>ADHD is a neurodevelopmental disorder that affects a person's ability to focus, control impulses, and regulate their activity levels.</p>.<p>It is one of the most common mental disorders affecting children. </p>
<p>New Delhi: Glenmark Pharmaceuticals is recalling close to 15 lakh bottles of a generic medication used in the treatment of attention deficit hyperactivity disorder in the US market, according to the US health regulator.</p>.<p>Glenmark Pharmaceuticals Inc, USA, a subsidiary of the Mumbai-based drug maker, is recalling around 14.76 lakh bottles of Atomoxetine Capsules in multiple strengths.</p>.<p>The company is recalling the affected lot due to "CGMP Deviations", the US Food and Drug Administration (USFDA) said in its latest Enforcement Report.</p>.Glenmark, Cosmo get MHRA nod for acne treatment medication.<p>The recall is due to "presence of N-Nitroso Atomoxetine impurity above the FDA recommended limit," it added.</p>.<p>New Jersey-based Glenmark Pharmaceuticals Inc, USA is recalling the made-in-India product in strengths ranging from 10 mg to 100 mg, USFDA stated.</p>.<p>The company initiated the Class II recall on January 29 this year.</p>.<p>As per the USFDA, a Class II recall is initiated in a situation in which use of, or exposure to, a violative product may cause temporary or medically reversible adverse health consequences or where the probability of serious adverse health consequences is remote.</p>.<p>ADHD is a neurodevelopmental disorder that affects a person's ability to focus, control impulses, and regulate their activity levels.</p>.<p>It is one of the most common mental disorders affecting children. </p>